{"id":"byetta-treatment","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Nausea"},{"rate":"10-15","effect":"Vomiting"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Hypoglycemia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2401866","moleculeType":"Protein","molecularWeight":"3904.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exenatide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also slows gastric emptying and reduces glucagon secretion, leading to improved glycemic control. The drug is derived from exendin-4, a peptide found in Gila monster venom.","oneSentence":"Byetta (exenatide) is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion in response to elevated blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:32.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT05663515","phase":"","title":"A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Pancreatic Cancer","enrollment":24000},{"nctId":"NCT05356104","phase":"PHASE2","title":"GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-05-25","conditions":"Cerebral Small Vessel Disease","enrollment":110},{"nctId":"NCT04897802","phase":"PHASE4","title":"Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-09-13","conditions":"Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism","enrollment":42},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT04520490","phase":"PHASE3","title":"Brain Activation and Satiety in Children 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2021-01-28","conditions":"Childhood Obesity","enrollment":63},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":241981},{"nctId":"NCT05670379","phase":"PHASE1","title":"Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant","status":"COMPLETED","sponsor":"Vivani Medical, Inc","startDate":"2024-12-20","conditions":"Overweight and Obesity, Type2diabetes","enrollment":24},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT06254014","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-10","conditions":"Type 2 Diabetes Mellitus","enrollment":270},{"nctId":"NCT06256419","phase":"NA","title":"Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2024-01-01","conditions":"Type 2 Diabetes Mellitus, Susceptibility, Genetic","enrollment":300},{"nctId":"NCT06257966","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-17","conditions":"Type2 Diabetes Mellitus","enrollment":600},{"nctId":"NCT04431713","phase":"PHASE2","title":"Exenatide Once-weekly as a Treatment for Multiple System Atrophy","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-09-16","conditions":"Multiple System Atrophy","enrollment":50},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT04154072","phase":"PHASE2","title":"A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease","status":"COMPLETED","sponsor":"Neuraly, Inc.","startDate":"2020-02-27","conditions":"Parkinson Disease","enrollment":255},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT02673931","phase":"NA","title":"GLP-1 and Hyperoxia for Organ Protection in Heart Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2016-02","conditions":"Coronary Disease, Shock, Cardiogenic, Renal Failure","enrollment":1400},{"nctId":"NCT06247748","phase":"PHASE1","title":"Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects","status":"COMPLETED","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 2, Overweight","enrollment":28},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT02157974","phase":"PHASE2, PHASE3","title":"Liver and Fat Regulation in Overweight Adolescent Girls","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-08","conditions":"Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity","enrollment":92},{"nctId":"NCT03923114","phase":"NA","title":"Imaging Pituitary ActiVation by Exendin","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-05-23","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT05347147","phase":"PHASE3","title":"A Trial to Determine the Efficacy and Safety of Presendin in IIH","status":"TERMINATED","sponsor":"Invex Therapeutics Ltd.","startDate":"2022-11-18","conditions":"Idiopathic Intracranial Hypertension","enrollment":14},{"nctId":"NCT03029351","phase":"PHASE4","title":"GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"University at Buffalo","startDate":"2017-01-10","conditions":"Type2 Diabetes, Kidney Diseases","enrollment":15},{"nctId":"NCT02962492","phase":"NA","title":"An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2016-11-01","conditions":"Evaluate Ketogenic Stress","enrollment":70},{"nctId":"NCT05136287","phase":"","title":"SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.","status":"COMPLETED","sponsor":"Jose Seijas Amigo","startDate":"2022-02-01","conditions":"Weight Loss, Diabetes Mellitus, Type 2, Quality of Life","enrollment":140},{"nctId":"NCT04232969","phase":"PHASE3","title":"Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease","status":"UNKNOWN","sponsor":"University College, London","startDate":"2020-01-20","conditions":"Parkinson's Disease","enrollment":194},{"nctId":"NCT04615910","phase":"PHASE2","title":"A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2021-07-01","conditions":"Diabetes Mellitus","enrollment":30},{"nctId":"NCT03151005","phase":"PHASE4","title":"The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2017-07-01","conditions":"Polycystic Ovary Syndrome (PCOS), Overweight, Obesity","enrollment":70},{"nctId":"NCT04504396","phase":"PHASE3","title":"Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-06-23","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":620},{"nctId":"NCT04504370","phase":"PHASE3","title":"Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2020-04-27","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":273},{"nctId":"NCT02981069","phase":"PHASE4","title":"Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":90},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT01511393","phase":"","title":"An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2012-01","conditions":"Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma","enrollment":6750},{"nctId":"NCT01416649","phase":"","title":"Impact of Exenatide on Sleep Duration","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-02-01","conditions":"Type 2 Diabetes","enrollment":8},{"nctId":"NCT02621489","phase":"PHASE4","title":"Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-12","conditions":"Atherosclerosis, Diabetes, Restenosis","enrollment":38},{"nctId":"NCT02829502","phase":"PHASE2","title":"The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke","status":"UNKNOWN","sponsor":"Christina Kruuse","startDate":"2016-08","conditions":"Ischemic Stroke","enrollment":30},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT02302976","phase":"PHASE1","title":"GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-11","conditions":"Cocaine Dependence","enrollment":13},{"nctId":"NCT05034783","phase":"EARLY_PHASE1","title":"[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"Insulinoma","enrollment":20},{"nctId":"NCT04305002","phase":"PHASE2","title":"Exenatide Treatment in Parkinson's Disease","status":"UNKNOWN","sponsor":"Center for Neurology, Stockholm","startDate":"2020-01-21","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT04941521","phase":"PHASE1, PHASE2","title":"Exenatide for Treating Cocaine Use Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-06-24","conditions":"Cocaine Use Disorder","enrollment":3},{"nctId":"NCT03350191","phase":"PHASE1","title":"A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-12-20","conditions":"Type 2 Diabetes Mellitus","enrollment":13},{"nctId":"NCT03007329","phase":"PHASE4","title":"Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-03-08","conditions":"Steatosis, Liver, Type2 Diabetes","enrollment":34},{"nctId":"NCT04969627","phase":"PHASE4","title":"Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.","status":"COMPLETED","sponsor":"Bing He","startDate":"2021-01-04","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT05328843","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function","status":"UNKNOWN","sponsor":"PegBio Co., Ltd.","startDate":"2022-05-01","conditions":"Type2Diabetes","enrollment":24},{"nctId":"NCT02194595","phase":"PHASE3","title":"Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT03645408","phase":"PHASE1","title":"The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-05-02","conditions":"Alcohol Use Disorder","enrollment":8},{"nctId":"NCT00882050","phase":"PHASE1, PHASE2","title":"Intravenous Exenatide (Byetta) During Surgery","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2009-03","conditions":"Euglycemia, Hypoglycemia, Hyperglycemia","enrollment":104},{"nctId":"NCT02417142","phase":"PHASE4","title":"Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2014-09","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":70},{"nctId":"NCT02496611","phase":"PHASE2","title":"Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2015-12","conditions":"Severe Obesity","enrollment":100},{"nctId":"NCT03970044","phase":"PHASE4","title":"Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.","status":"COMPLETED","sponsor":"Consano Clinical Research, LLC","startDate":"2019-07-02","conditions":"Diabetes Mellitus, Type 2","enrollment":67},{"nctId":"NCT01590433","phase":"PHASE4","title":"Weight Loss With Exenatide Treatment","status":"COMPLETED","sponsor":"Jody Dushay","startDate":"2012-03","conditions":"Obesity","enrollment":249},{"nctId":"NCT03232112","phase":"PHASE2","title":"Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?","status":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2017-08-07","conditions":"Alcohol Dependence, in Remission, Addiction, Alcohol","enrollment":152},{"nctId":"NCT03167411","phase":"PHASE1","title":"Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-05-24","conditions":"Type2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02119819","phase":"PHASE2","title":"A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2","enrollment":420},{"nctId":"NCT02685852","phase":"PHASE1","title":"Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2016-02","conditions":"Hyperinsulinemic Hypoglycemia","enrollment":11},{"nctId":"NCT04269642","phase":"PHASE2","title":"SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Peptron, Inc.","startDate":"2020-03-19","conditions":"Early Parkinson's Disease","enrollment":99},{"nctId":"NCT03671733","phase":"PHASE3","title":"Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2018-09-01","conditions":"Obesity","enrollment":150},{"nctId":"NCT00566813","phase":"PHASE1, PHASE2","title":"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT02432976","phase":"PHASE2, PHASE3","title":"Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2015-05","conditions":"Quality of Life","enrollment":64},{"nctId":"NCT02975297","phase":"PHASE1, PHASE2","title":"Exenatide Once Weekly for Smoking Cessation","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-07","conditions":"Smoking Cessation","enrollment":84},{"nctId":"NCT00658021","phase":"PHASE3","title":"Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-05-30","conditions":"Type 2 Diabetes","enrollment":122},{"nctId":"NCT02404376","phase":"PHASE3","title":"COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2016-03","conditions":"ST Elevation Acute Myocardial Infarction","enrollment":378},{"nctId":"NCT02802514","phase":"PHASE4","title":"A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-09-20","conditions":"Diabetes Mellitus","enrollment":5},{"nctId":"NCT00799435","phase":"PHASE4","title":"Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2, Heart Failure, Diastolic","enrollment":2},{"nctId":"NCT04303819","phase":"","title":"The Effect of Exenatide on Fasting Bile Acids","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2020-01-05","conditions":"Type 2 Diabetes Mellitus in Obese","enrollment":38},{"nctId":"NCT03419624","phase":"PHASE3","title":"The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2018-02-19","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":13},{"nctId":"NCT01724060","phase":"","title":"Effects of Obesity Treatments on Food Preferences and Metabolism","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-09","conditions":"Obesity, Type 2 Diabetes Mellitus","enrollment":80},{"nctId":"NCT03444142","phase":"PHASE4","title":"Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes","status":"UNKNOWN","sponsor":"University of Guadalajara","startDate":"2017-11-17","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT01928329","phase":"PHASE2","title":"A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-09","conditions":"Type I Diabetes","enrollment":79},{"nctId":"NCT04184947","phase":"","title":"Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists","status":"COMPLETED","sponsor":"University of Padova","startDate":"2014-03-01","conditions":"Type 2 Diabetes","enrollment":10000},{"nctId":"NCT02690883","phase":"PHASE4","title":"Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-04-08","conditions":"Diabetic Nephropathies","enrollment":92},{"nctId":"NCT03804411","phase":"PHASE4","title":"Prognostic Predictors of Response to Hypoglycemic Therapy","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":800},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02020616","phase":"PHASE1, PHASE2","title":"A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT03352869","phase":"PHASE4","title":"Research of Exenatide for Overweight/Obese PCOS Patients With IGR","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2017-11-28","conditions":"Polycystic Ovary Syndrome, Overweight and Obesity, Disorder of Glucose Regulation","enrollment":183},{"nctId":"NCT04029272","phase":"PHASE4","title":"Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-07-20","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT03017352","phase":"PHASE2","title":"Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases","status":"COMPLETED","sponsor":"Filip Krag Knop","startDate":"2016-12","conditions":"Diabetes Mellitus, Type 1","enrollment":108},{"nctId":"NCT02455076","phase":"PHASE4","title":"Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT03959865","phase":"","title":"GLP-1 REceptor Agonists and Real World EvIdeNce","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2018-12-19","conditions":"Type 2 Diabetes","enrollment":6000},{"nctId":"NCT01687582","phase":"NA","title":"Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2012-01","conditions":"Type 2 Diabetes, Psoriasis","enrollment":10},{"nctId":"NCT03060980","phase":"PHASE3","title":"Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin","status":"TERMINATED","sponsor":"Intarcia Therapeutics","startDate":"2017-03-03","conditions":"Diabetes Mellitus, Type 2","enrollment":245},{"nctId":"NCT01785771","phase":"PHASE3","title":"A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c","status":"TERMINATED","sponsor":"Intarcia Therapeutics","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT02229383","phase":"PHASE3","title":"Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-06","conditions":"Diabetes Mellitus","enrollment":464},{"nctId":"NCT01676116","phase":"PHASE3","title":"The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":438},{"nctId":"NCT02229396","phase":"PHASE3","title":"Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-04","conditions":"Diabetes Mellitus","enrollment":695},{"nctId":"NCT02860923","phase":"PHASE3","title":"Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2017-01-11","conditions":"Craniopharyngiomas, Hypothalamic Obesity","enrollment":42},{"nctId":"NCT01136798","phase":"NA","title":"Impact of Exenatide on Sleep in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2010-06-01","conditions":"Type 2 Diabetes, Sleep Disordered Breathing","enrollment":18},{"nctId":"NCT01144338","phase":"PHASE3","title":"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06-18","conditions":"Type 2 Diabetes Mellitus","enrollment":14752},{"nctId":"NCT00845507","phase":"PHASE4","title":"Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2008-12","conditions":"Weight Gain","enrollment":54},{"nctId":"NCT02735031","phase":"PHASE2, PHASE3","title":"Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-02-21","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia","enrollment":10},{"nctId":"NCT01269047","phase":"PHASE4","title":"Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2009-08","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT02917057","phase":"","title":"Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-01","conditions":"Type 2 Diabetes","enrollment":6024},{"nctId":"NCT01046721","phase":"NA","title":"Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2009-09","conditions":"Type 2 Diabetes","enrollment":8},{"nctId":"NCT03383068","phase":"PHASE4","title":"Research of Intensive Metabolic Intervention Before Pregnancy in PCOS","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2018-01-01","conditions":"PCOS, Impaired Glucose Tolerance","enrollment":160},{"nctId":"NCT02843399","phase":"","title":"Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-08-15","conditions":"Diabetes Mellitus Type 2","enrollment":15498}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BYETTA treatment","genericName":"BYETTA treatment","companyName":"Assistance Publique Hopitaux De Marseille","companyId":"assistance-publique-hopitaux-de-marseille","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BYETTA is a treatment that targets the protein modality to help manage conditions such as diabetes mellitus, impaired glucose tolerance, and type 2 diabetes. It is administered as an extended-release exenatide, which is a form of the protein exenatide.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}